Clinical Trial Update: Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating induction therapy with lenalidomide, bortezomib, and dexamethasone plus isatuximab given either intravenously or subcutaneously in pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• Dexamethasone (Decadron) (dexamethasone)
• Isatuximab (Sarclisa) (isatuximab)
• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: University of Heidelberg Medical Center | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED